Addex Therapeutics Company Description

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.

Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.

The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Addex Therapeutics Ltd

Country	Switzerland
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	23
CEO	Timothy Dyer

Contact Details

Address: Chemin des Mines, 9 Geneva, 1202 Switzerland
Phone	41 22 884 1555
Website	addextherapeutics.com

Stock Details

Ticker Symbol	ADXN
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH0029850754
SIC Code	2834

Key Executives

Name	Position
Timothy Mark Dyer	Co-Founder, Chief Executive Officer and Director
Dr. Roger G. Mills M.D.	Chief Medical Officer and Director
Lénaic Teyssédou	Head of Finance
Dr. Mikhail Kalinichev Ph.D.	Head of Translational Science